STEAP1
STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
Six-transmembrane epithelial antigen of the prostate 1 is expressed in >80% of prostate cancers including PSMA-low and neuroendocrine-like disease, with limited normal expression. Xaluritamig (STEAP1×CD3 XmAb 2+1) produced PSA50 in ~half of heavily pretreated mCRPC patients at target doses in phase 1 and is in two phase 3 trials (XALute post-taxane; XALience with abiraterone chemo-naive). Also an ADC target historically (vandortuzumab vedotin, discontinued).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
- 1 · What it is
STEAP1 is a protein on the surface of most prostate cancer cells, now the address for a T-cell engager in phase 3.
- 2 · What goes wrong in cancer
STEAP1 is a metalloreductase at cell junctions, upregulated by androgen receptor signalling; its expression is partly independent of PSMA, making it complementary.
- 3 · How drugs use it
1 product aims at STEAP1: bispecific antibodies. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
STEAP1 is a metalloreductase at cell junctions, upregulated by androgen receptor signalling; its expression is partly independent of PSMA, making it complementary.
- Prostate cancer (>80%)
- Ewing sarcoma
- Bladder (subset)
Latest papers
topQuery for this target: (TITLE:"STEAP1" OR ABSTRACT:"STEAP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STEAP1, not a curated reading list.